{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,23]],"date-time":"2025-05-23T16:36:24Z","timestamp":1748018184535,"version":"3.40.5"},"reference-count":31,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"48","license":[{"start":{"date-parts":[[2024,11,29]],"date-time":"2024-11-29T00:00:00Z","timestamp":1732838400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,11,29]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>To systematically assess the cost-effectiveness of immune checkpoint inhibitors compared to the current standard therapy for human papillomavirus (HPV) and human immunodeficiency virus (HIV)-related cervical cancer.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>A partitioned survival model spanning a 20-year period was created to evaluate the cost and effectiveness of atezolizumab combined with bevacizumab and chemotherapy (ABC), and pembrolizumab combined with bevacizumab and chemotherapy (PBC) vs bevacizumab combined with chemotherapy (BC), based on clinical data from the BEATcc and KEYNOTE-826 trials. Royston-Parmar models were used for survival estimation. Costs and health state utilities were sourced from existing literature and publicly accessible databases. Cumulative costs (in US dollars), life years, quality-adjusted life years (QALYs), and incremental cost-effectiveness ratios (ICERs) were measured and compared. The evaluation was from the US healthcare payer perspective, with the willingness-to-pay threshold set at $100,000 to $150,000. Deterministic sensitivity analysis (DSA), probabilistic sensitivity analysis (PSA), and scenario analyses were conducted.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>The base-case analysis showed QALYs of 2.05 for BC, 3.18 for PBC, and 2.85 for ABC. PBC increased life-years by 1.76 and ABC by 1.18, with PBC showing the highest effectiveness. Total costs were $272,377 for BC, $715,472 for ABC, and $694,239 for PBC; severe adverse event (SAE) costs were $6189 for BC, $7603.31 for ABC, and $13,640 for PBC, indicating BC had the lowest SAE costs. The ICERs compared to BC were $372,151\/QALY for PBC and $553,995\/QALY for ABC. Given that the willingness-to-pay threshold was $100,000 to $150,000\/QALY, both PBC and ABC exceed this threshold and were not considered cost-effective. BC had the lowest QALYs and the lowest costs, making it the least expensive option and the most cost-effective choice. DSA results indicated that drug prices and utility values were the main factors affecting cost-effectiveness. PSA confirmed BC as the most cost-effective option within a willingness-to-pay threshold of $0 to $300,000, primarily because it was the least costly.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>Immune checkpoint inhibitors significantly improve survival benefits for patients. However, their addition is costly and unlikely to be cost-effective for HPV\/HIV-related metastatic cervical cancer.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000040678","type":"journal-article","created":{"date-parts":[[2024,11,29]],"date-time":"2024-11-29T21:03:58Z","timestamp":1732914238000},"page":"e40678","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Cost-effectiveness analysis of immune checkpoint inhibitors combined with targeted therapy and chemotherapy for HPV\/HIV-related cervical cancer"],"prefix":"10.1097","volume":"103","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7709-9374","authenticated-orcid":false,"given":"Yuqing","family":"Liang","sequence":"first","affiliation":[{"name":"Department of Pharmacoeconomics, School of International Pharmaceutical Business, China Pharmaceutical University, Nanjing, Jiangsu, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aixia","family":"Ma","sequence":"additional","affiliation":[{"name":"Department of Pharmacoeconomics, School of International Pharmaceutical Business, China Pharmaceutical University, Nanjing, Jiangsu, China"},{"name":"Center for Pharmacoeconomics and Outcomes Research, China Pharmaceutical University, Nanjing, Jiangsu, China."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20250503","doi-asserted-by":"crossref","first-page":"e197","DOI":"10.1016\/S2214-109X(22)00501-0","article-title":"Global estimates of incidence and mortality of cervical cancer in 2020: a baseline analysis of the WHO Global Cervical Cancer Elimination Initiative.","volume":"11","author":"Singh","year":"2023","journal-title":"Lancet Glob Health"},{"key":"R2-20250503","doi-asserted-by":"crossref","first-page":"e191","DOI":"10.1016\/S2214-109X(19)30482-6","article-title":"Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis.","volume":"8","author":"Arbyn","year":"2020","journal-title":"Lancet Glob Health"},{"issue":"suppl_4","key":"R3-20250503","doi-asserted-by":"crossref","first-page":"iv72","DOI":"10.1093\/annonc\/mdx220","article-title":"Cervical cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.","volume":"28","author":"Marth","year":"2017","journal-title":"Ann Oncol"},{"key":"R4-20250503","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1056\/NEJMoa1309748","article-title":"Improved survival with bevacizumab in advanced cervical cancer.","volume":"370","author":"Tewari","year":"2014","journal-title":"N Engl J Med"},{"key":"R5-20250503","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1016\/S0140-6736(17)31607-0","article-title":"Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240).","volume":"390","author":"Stehman","year":"2017","journal-title":"Lancet"},{"key":"R6-20250503","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1056\/NEJMoa2112435","article-title":"Pembrolizumab for persistent, recurrent, or metastatic cervical cancer.","volume":"385","author":"Colombo","year":"2021","journal-title":"N Engl J Med"},{"key":"R7-20250503","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(23)02405-4","article-title":"Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial.","volume":"403","author":"Oaknin","year":"2024","journal-title":"Lancet"},{"key":"R8-20250503","doi-asserted-by":"crossref","first-page":"815587","DOI":"10.3389\/fonc.2022.815587","article-title":"Cost-effectiveness of pembrolizumab for the treatment of non-small-cell lung cancer: a systematic review.","volume":"12","author":"Zhang","year":"2022","journal-title":"Front Oncol"},{"key":"R9-20250503","first-page":"80","article-title":"Financial toxicity, Part I: a new name for a growing problem.","volume":"27","author":"Zafar","year":"2013","journal-title":"Oncology (Williston Park)"},{"key":"R10-20250503","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1056\/NEJMp1405158","article-title":"Updating cost-effectiveness--the curious resilience of the $50,000-per-QALY threshold.","volume":"371","author":"Neumann","year":"2014","journal-title":"N Engl J Med"},{"key":"R11-20250503","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.gore.2017.05.004","article-title":"Apparent ectopic pregnancy with unexpected finding of a germ cell tumor: a case report.","volume":"21","author":"Kucera","year":"2017","journal-title":"Gynecol Oncol Rep"},{"key":"R12-20250503","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1002\/cncy.21463","article-title":"The low risk of precancer after a screening result of human papillomavirus-negative\/atypical squamous cells of undetermined significance papanicolaou and implications for clinical management.","volume":"122","author":"Gage","year":"2014","journal-title":"Cancer Cytopathol"},{"key":"R13-20250503","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1177\/0272989X16670617","article-title":"Estimation of survival probabilities for use in cost-effectiveness analyses: a comparison of a multi-state modeling survival analysis approach with partitioned survival and Markov decision-analytic modeling.","volume":"37","author":"Williams","year":"2017","journal-title":"Med Decis Making"},{"key":"R14-20250503","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1007\/s40273-013-0064-3","article-title":"Overview of parametric survival analysis for health-economic applications.","volume":"31","author":"Ishak","year":"2013","journal-title":"PharmacoEcon"},{"key":"R15-20250503","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1001\/jama.2016.12195","article-title":"Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: second panel on cost-effectiveness in health and medicine.","volume":"316","author":"Sanders","year":"2016","journal-title":"JAMA"},{"key":"R16-20250503","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1471-2288-12-9","article-title":"Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves.","volume":"12","author":"Guyot","year":"2012","journal-title":"BMC Med Res Methodol"},{"key":"R17-20250503","doi-asserted-by":"crossref","first-page":"e36387","DOI":"10.1097\/MD.0000000000036387","article-title":"Sotorasib versus Docetaxel for treatment of US and Chinese patients with advanced non-small-cell lung cancer with KRAS p.G12C-mutated: a cost-effectiveness analysis to inform drug pricing.","volume":"102","author":"Jiang","year":"2023","journal-title":"Medicine (Baltim)"},{"key":"R18-20250503","doi-asserted-by":"crossref","first-page":"869960","DOI":"10.3389\/fpubh.2022.869960","article-title":"Cost-effectiveness analysis of five systemic treatments for unresectable hepatocellular carcinoma in China: an economic evaluation based on network meta-analysis.","volume":"10","author":"Zhao","year":"2022","journal-title":"Front Public Health"},{"key":"R19-20250503","article-title":"ASP drug pricing files."},{"key":"R20-20250503","article-title":"Physician fee schedule search."},{"key":"R21-20250503","article-title":"The United States Consumer Price Index (CPI)."},{"key":"R22-20250503","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.ygyno.2021.12.007","article-title":"Cost-effectiveness analysis of pembrolizumab for treatment of US patients with persistent, recurrent, or metastatic cervical cancer.","volume":"164","author":"Shi","year":"2022","journal-title":"Gynecol Oncol"},{"key":"R23-20250503","doi-asserted-by":"crossref","first-page":"1758835920916000","DOI":"10.1177\/1758835920916000","article-title":"Cost-effectiveness of adding atezolizumab to first-line chemotherapy in patients with advanced triple-negative breast cancer.","volume":"12","author":"Wu","year":"2020","journal-title":"Ther Adv Med Oncol"},{"year":"2023","key":"R24-20250503","article-title":"Physician fee schedule search."},{"year":"2023","key":"R25-20250503","article-title":"Physician fee schedule search."},{"key":"R26-20250503","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.jval.2021.08.009","article-title":"Cost-effectiveness of cemiplimab versus standard of care in the united states for first-line treatment of advanced non-small cell lung cancer with programmed death-ligand 1 expression \u226550.","volume":"25","author":"Kuznik","year":"2022","journal-title":"Value Health"},{"key":"R27-20250503","doi-asserted-by":"crossref","first-page":"37","DOI":"10.2217\/imt-2019-0199","article-title":"Clinical and economic outcomes of treatment sequences for intermediate- to poor-risk advanced renal cell carcinoma.","volume":"12","author":"Ambavane","year":"2020","journal-title":"Immunotherapy"},{"key":"R28-20250503","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1007\/s41669-022-00348-0","article-title":"Cost-utility of nivolumab plus ipilimumab in first-line treatment of advanced melanoma in the United States: an analysis using long-term overall survival data from checkmate 067.","volume":"6","author":"Baker","year":"2022","journal-title":"PharmacoEcon Open"},{"key":"R29-20250503","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.ygyno.2015.02.027","article-title":"A Markov model to evaluate cost-effectiveness of antiangiogenesis therapy using bevacizumab in advanced cervical cancer.","volume":"137","author":"Minion","year":"2015","journal-title":"Gynecol Oncol"},{"key":"R30-20250503","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1016\/S0140-6736(17)31607-0","article-title":"Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240).","volume":"390","author":"Tewari","year":"2017","journal-title":"Lancet"},{"key":"R31-20250503","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.ygyno.2022.03.031","article-title":"Pembrolizumab with or without bevacizumab for recurrent or metastatic cervical cancer: a cost-effectiveness analysis.","volume":"165","author":"Barrington","year":"2022","journal-title":"Gynecol Oncol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000040678","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T00:03:13Z","timestamp":1746316993000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000040678"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,29]]},"references-count":31,"journal-issue":{"issue":"48","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000040678","relation":{},"ISSN":["1536-5964"],"issn-type":[{"type":"electronic","value":"1536-5964"}],"subject":[],"published":{"date-parts":[[2024,11,29]]}}}